| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 10/13/2004 | CN1170527C Therapeutic perparation for inhalation containing parathyroid hormone, PTH |
| 10/12/2004 | USRE38624 Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation |
| 10/12/2004 | US6803484 Sulfonamide derivatives |
| 10/12/2004 | US6803480 Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia |
| 10/12/2004 | US6803455 Inhibitors of nucleoside metabolism |
| 10/12/2004 | US6803380 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them |
| 10/12/2004 | US6803378 For therapy and prophylaxis of acquired immune deficiency syndrome (aids), or arc |
| 10/12/2004 | US6803372 Such as cis-n-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'h)-isobenzofuran)-4-carboxamide for use as neuropeptide y receptor antagonist for treatment bulimia, obesity or diabetes |
| 10/12/2004 | US6803365 Imidazo[1,3,5]triazinones and the use thereof |
| 10/12/2004 | US6803364 Il-5 inhibiting 6-azauracil derivatives |
| 10/12/2004 | US6803362 Heterocyclic compounds |
| 10/12/2004 | US6803359 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 10/12/2004 | US6803211 Cancer therapy |
| 10/12/2004 | US6803039 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM |
| 10/12/2004 | US6803031 Aerosol comprises particles comprising at least 10 percent by weight of an erectile dysfunction drug, such as sildenafil, tadalafil or vardenafil. |
| 10/12/2004 | CA2170394C Process for conditioning substances |
| 10/07/2004 | WO2004085632A1 Control of stem cell differentiation induction and differentiation potency |
| 10/07/2004 | WO2004085373A1 Novel shogaol compound and tyrosinase activity inhibitor comprising the compound |
| 10/07/2004 | WO2004084906A1 Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 10/07/2004 | WO2004084882A1 Use of arachidonic acid for normalization of infradian rhythm |
| 10/07/2004 | WO2004069999A3 Screening method |
| 10/07/2004 | WO2004026829A3 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors |
| 10/07/2004 | WO2004024880A3 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 10/07/2004 | WO2004012659A3 Nitrosated proton pump inhibitors, compositions and methods of use |
| 10/07/2004 | WO2004002418A3 Compositions and methods comprising protein activated receptor antagonists |
| 10/07/2004 | WO2004002402A3 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 10/07/2004 | WO2003105770A3 Carbocyclic nucleoside analogs as rna-antivirals |
| 10/07/2004 | WO2003101386A3 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 10/07/2004 | WO2003076427A8 Quinazoline compounds useful in therapy |
| 10/07/2004 | WO2003068748A9 Novel pyridine- and quinoline-derivatives |
| 10/07/2004 | WO2003059942A3 Peptides and peptidomimetics having anti-proliferative activity and their use |
| 10/07/2004 | WO2003057725A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 10/07/2004 | WO2003049679A3 Mitotic kinesin inhibitors |
| 10/07/2004 | WO2002088317A3 Fusion molecules and methods for treatment of immune diseases |
| 10/07/2004 | US20040198983 including fexofenadine; novel synthetic intermediate 2-(4-{4-(Hydroxydiphenyl-methyl)-piperidine-1-yl]-4-oxo-butyryl}-phenyl)-2-2-methyl-propionic Acid lower alkyl ester |
| 10/07/2004 | US20040198982 such as (4S)-1-(3-bromophenyl)-N-cyanomethyl)-4-methyl-prolinamide; for treatment of osteoporosis |
| 10/07/2004 | US20040198979 antagonists of urotensin II; (R) N-[4-Chloro-3-(1-methyl-3-pyrrolidinyloxy)-phenyl]-[3-(2-chlorophenoxy)]benzenesulfonamide for example; treating various disease including cardiovascular disorders, gastrointestinal disorders, and psychological disorders |
| 10/07/2004 | US20040198978 for treating autoimmune diseases selected from psoriasis, multiple sclerosis and rheumatoid arthritis; N-(3-oxoundecanoyl)-L-homoserine lactone (OuDHL) and 2-n-heptyl-3-hydroxy-4(1H)-quinolone for example |
| 10/07/2004 | US20040198961 Fce fusion proteins for treatment of allergy and asthma |
| 10/07/2004 | US20040198831 Remedial agent for arthrosis deformans |
| 10/07/2004 | US20040198824 enzyme inhibitor; anticancer agents; analgesics; vision defects |
| 10/07/2004 | US20040198820 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 10/07/2004 | US20040198816 Administering mixture of anesthetic and adrenergic receptor antagonist; reverse with low dosage of adrenergic receptor antagonist; used for hair grafting |
| 10/07/2004 | US20040198804 i.e., 3-[3,5-dimethyl-4-[3-oxo-3-(piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one, in which the piperazine may be 4-substituted with methyl or ethyl and salts are tyrosine kinase inhibitors used to treat various kinds of cancer |
| 10/07/2004 | US20040198801 Antiinflammatory agents; sepsis |
| 10/07/2004 | US20040198796 Compounds and methods for treating urinary incontinence |
| 10/07/2004 | US20040198783 Targeted bone marrow protection agents |
| 10/07/2004 | US20040198782 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration |
| 10/07/2004 | US20040198781 Carbonic anhydrase inhibitor |
| 10/07/2004 | US20040198776 Methods for increasing leptin levels using nicotinic acid compounds |
| 10/07/2004 | US20040198774 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity |
| 10/07/2004 | US20040198771 medical equipment for angioplasty |
| 10/07/2004 | US20040198764 Prodrugs of imidazopyridine derivatives |
| 10/07/2004 | US20040198757 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 10/07/2004 | US20040198751 Pyrazolo-pyrimidine compound; anticancer agents |
| 10/07/2004 | US20040198749 Methods of using sodium channel blockers |
| 10/07/2004 | US20040198748 Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders |
| 10/07/2004 | US20040198740 Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 |
| 10/07/2004 | US20040198738 Preventives or remedies for diseaes caused by enos expression |
| 10/07/2004 | US20040198737 Azaindoles |
| 10/07/2004 | US20040198735 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
| 10/07/2004 | US20040198730 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 10/07/2004 | US20040198726 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists |
| 10/07/2004 | US20040198722 Pyrrolobenzodiazepines on solid supports; |
| 10/07/2004 | US20040198720 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 10/07/2004 | US20040198718 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 10/07/2004 | US20040198717 4-(trifluoromethyl)-7,8,9,10-tetrahydrochromeno[7,6-b]azepin-2(6H)-one and derivatives;4-(trifluoromethyl)-1,6,7,8,9,10-hexahydro-2H-azepino[3,2-g]quinolin-2-one and derivatives; useful in the treating conditions caused by androgen deficiency such as bone disorders |
| 10/07/2004 | US20040198696 Agent and food for inhibiting IgE antibody |
| 10/07/2004 | US20040198688 for treatment of atopic conditions (dermatitis, allergies); point mutations |
| 10/07/2004 | US20040198674 Compositions for preventing hormone induced adverse effects |
| 10/07/2004 | US20040198662 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; anticholesterol agents; hypercholesterolemia, cardiovascular disorders, atherosclerosis, restenosis, hypertriglyceridemia, high density lipoprotein deficiency, metabolic disorders |
| 10/07/2004 | US20040198659 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 10/07/2004 | US20040198658 Stanniocalcin polynucleotides, polypeptides and methods based thereon |
| 10/07/2004 | US20040198653 administering somatostatin type-1,2 or 5 receptor oligopeptide agonists alone or in synergistic combination; antiproliferative agents |
| 10/07/2004 | US20040198651 Secreted proteins |
| 10/07/2004 | US20040197889 cell free hepatitis b virus transcription/translation in escherichia plasmid; enzyme inhibitors; mimetics; viricides; shelf life |
| 10/07/2004 | US20040197876 Recombinant fusion proteins and the trimers thereof |
| 10/07/2004 | US20040197860 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 10/07/2004 | US20040197853 largely reduced of antigenicity compared to native trichosanthin (TCS), while retaining anti-tumor, anti-virus, abortifacient, and ribosome-inactivating protein activities; for treating leukemia |
| 10/07/2004 | US20040197847 High throughput screening assays using fatty acid synthetic enzymes |
| 10/07/2004 | US20040197827 Contacting with Ewing sarcoma protein and nuclear receptor; determining binding and changes in ligand-induced activity; use in diagnosis and treatment |
| 10/07/2004 | US20040197786 Method of examining steroid resnponsiveness |
| 10/07/2004 | US20040197429 Selective COX-2 inhibition from plant extracts |
| 10/07/2004 | US20040197427 Herbal composition for improving anticancer activity, immune response and hematopoiesis of the body, and protecting the body from oxidative damage, and the method of preparing the same |
| 10/07/2004 | US20040197426 Use of phyllanthus constituents for treating or preventing infections caused by hepatit |
| 10/07/2004 | US20040197416 contains dehydroepiandrosterone (DHEA) or its derivatives, aqueous medium, a polymer shell and a lipid core containing an oily solvent |
| 10/07/2004 | US20040197409 a prosthetic device (sleeve) placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material; flexible, cylindrical, bioabsorbing, agent-eluting matrix with a vascular-sized lumen |
| 10/07/2004 | US20040197406 Stool softener and enteric coated bisacodyl; tablets, capsule; laxative; administering the drug |
| 10/07/2004 | US20040197405 Multiparticulate modified release composition |
| 10/07/2004 | US20040197404 Extended release oral dosage form |
| 10/07/2004 | US20040197360 Hybrid composite dispersion; polycarbonateether block copolymer in aqueous solution |
| 10/07/2004 | US20040197345 Prostate derived Ets factor |
| 10/07/2004 | US20040197338 Sequening peptide fragments which bind to proteins; prevention reproduction of respiratory syncytial virus |
| 10/07/2004 | US20040197337 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 10/07/2004 | US20040197335 Non-myeloablative tolerogenic treatment with tyrphostins |
| 10/07/2004 | US20040197332 antiproliferative agents; antitumor and anticancer agents; monoclonal antibodies produced by hybridomas cell ling |
| 10/07/2004 | US20040197314 gene expression of polypeptide in membrane vesicle ; forming antibodies; controlling immunology response |
| 10/07/2004 | US20040197309 Schwann cells originating in myeloid interstitial cells |
| 10/07/2004 | US20040197307 Mixture of human interferons |
| 10/07/2004 | US20040197303 For therapy of inflammation and diseases or conditions associated with autoimmune responses |